Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies

Head and Neck

Volumn 34, Issue 6, 2012, Pages 872-876

  Rosenberg, Lewis ^a   Weissler, Mark ^a   Hayes, D Neil ^a   Shockley, William ^a   Zanation, Adam ^a   Rosenman, Julian ^a   Chera, Bhishamjit ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

chemoradiation; concurrent chemotherapy; multimodality therapy; salivary gland malignancy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER PATIENT; CANCER RISK; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; HUMAN; INOPERABLE CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SALIVARY GLAND CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS;

EID: 84861333085     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21831     Document Type: Article

References (25)

1. Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 2nd ed. Philadelphia: Elsevier; 2007.
2. Tran L, Sadeghi A, Hanson D, et al. Major salivary gland tumors: treatment results and prognostic factors. Laryngoscope 1986; 96: 1139-1144.
3. Theriault C, Fitzpatrick PJ,. Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 1986; 9: 510-516.
4. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004; 26: 681-692; discussion 692-693.
5. Ma'aita JK, Al-Kaisi N, Al-Tamimi S, Wraikat A,. Salivary gland tumors in Jordan: a retrospective study of 221 patients. Croat Med J 1999; 40: 539-542.
6. Frankenthaler RA, Luna MA, Lee SS, et al. Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg 1991; 117: 1251-1256.
7. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY,. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 1990; 116: 290-293.
8. Cheung MC, Franzmann E, Sola JE, Pincus DJ, Koniaris LG,. A comprehensive analysis of parotid and salivary gland cancer: worse outcomes for male gender. J Surg Res 2010 [Epub ahead of print].
9. Bell RB, Dierks EJ, Homer L, Potter BE,. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005; 63: 917-928.
10. Pignon JP, le Maitre A, Maillard E, Bourhis J,. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
11. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
12. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
13. Laurie SA, Licitra L,. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006; 24: 2673-2678.
14. AJCC cancer staging manual. New York: Springer; 2009.
15. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
16. Vale C,. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-5812.
17. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
18. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
19. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
20. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68: 1874-1877.
21. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993; 4: 785-788.
22. Katori H, Tsukuda M,. Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma. Acta Otolaryngol 2006; 126: 1309-1314.
23. Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009; 135: 687-692.
24. Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 2010; 95: 308-311.
25. Cited with permission from The NCCN 2.2010 Head and Neck Cancer Clinical Practice Guidelines in Oncology. ©National Comprehensive Cancer Network, 2010. Available at:. To view the most recent and complete version of the guideline, go to.